Clinical Trial

A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease

Study acronym: IgG4-RD
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
For patients with active proliferative IgG4-RD, we plan to conduct a 52-week prospective randomized controlled trial to compare the efficacy and safety of 5mg lenalidomide plus prednisone, 10mg lenalidomide plus prednisone, and prednisone alone, so as to find new treatment measures for patients with proliferative IgG4-RD.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-07.
Trial Details
NCT Number NCT07068165
Lead Sponsor Peking Union Medical College Hospital
Conditions IgG4 Related Disease
Enrollment 198 participants
Start Date 2025-07-07
Primary Completion 2028-07-20 (estimated)
Study Completion 2028-08-20 (estimated)
Updated on ClinicalTrials.gov 2025-12-30